Insulin glargine

California Selects Civica Rx as Its Insulin Manufacturing Partner

Retrieved on: 
Saturday, March 18, 2023
Public Policy, Government, Pharmaceutical, State, Local, Managed Care, Health, Diabetes, Healthcare Reform, Hospitals, Insulin, Inc., Partnership, Insulin lispro, Patient, Risk, Insulin aspart, Pharmaceutical industry, Civica, Insulin glargine

Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

Key Points: 
  • Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
  • “California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom.
  • Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices.
  • The next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Retrieved on: 
Thursday, March 16, 2023
Pharmacy, Inflation Reduction Act of 2022, Medicare, Patient, Insulin, CMS, Insurance, Inflation, Medicaid, Policy, Pharmaceutical industry, Health insurance, Sanofi, Insulin glargine/lixisenatide, Insulin glargine

Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Key Points: 
  • Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
    Paris, March 16, 2023.
  • Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent.
  • The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines.
  • Finally, Sanofi will also cut the list price of its short-acting Apidra (insulin glulisine injection) 100 Units/mL by 70%.

Insulin Drugs Global Market Report 2023

Retrieved on: 
Monday, February 20, 2023
Pharmacy, Diabetes, Type, Safety, Eli Lilly and Company, Acquisition, Cell, JAMA, Research report, Insulin, Overweight, Novo Nordisk, Insulin (medication), Lilly, Prediabetes, Insulin glargine/lixisenatide, Gestational diabetes, Pancreas, Growth, Prevalence, Organization, Investment, Obesity, Patient, Insulin degludec/insulin aspart, Geography, Research, Gene, COVID-19, Uncertainty, Woman, Type 1 diabetes, World Health Organization, Drug development, CRISPR, WHO, Insulin detemir, DSM-IV codes, Pharmaceutical industry, Medical device, Dietary supplement, Insulin lispro, Insulin glargine

The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.

Key Points: 
  • The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.
  • The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The insulin drugs market research report is one of a series of new reports that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry.
  • This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences

Retrieved on: 
Friday, November 18, 2022
Capital Magazine, Intellectual property, LMG, Human Capital (magazine), Dimethyl fumarate, Insulin glargine, Geography, Good, IP, Pleasure, Patent, Sustainability reporting, Multimedia, Patient, Certification, COVID-19, Best Employers in Canada, Global health, Pharmaceutical industry, Newsweek, Viatris

In-House Legal Team of the Year for Intellectual Property Litigation after achieving significant victories in several patent litigation matters.

Key Points: 
  • In-House Legal Team of the Year for Intellectual Property Litigation after achieving significant victories in several patent litigation matters.
  • "Our Intellectual Property Litigation group has always operated on the foundation of respecting legitimate, valid intellectual property rights.
  • It is truly a pleasure to see our entire IP litigation team be recognized as In-House Legal Team of the Year."
  • Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life.

Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Pharmaceutical, United Nations, Erythropoietin, Biocon, Infection, National Health Research Institutes, Growth, Patient, Application, Insulin, CAGR, Growth hormone, Insulin glargine, Maintenance, Cancer, Asthma, Immune system, PCP, Conditional sentence, Arthritis, COVID-19, Degenerative disease, Partnership, PricewaterhouseCoopers, Prevalence, Mylan, Awareness, Safety, Generic drug, Vaccine

The "Biosimilars Global Market Report 2022: By Product, By Types, By Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilars Global Market Report 2022: By Product, By Types, By Application" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market.
  • Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.
  • The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market.

LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM

Retrieved on: 
Monday, November 7, 2022
Harsco Infrastructure Deutschland GmbH, Company, Sanofi, Insulin glargine, Biologics license application, Risk, FDA, NYSE, BLA, HEC, LCI, News, SEC, Fine chemical, Pharmaceutical industry

Under the agreement, Lannett and HEC will, in exchange for its financial contribution, receive a sub-license to a licensing arrangement between Ypsomed and Sanofi-Aventis Deutschland GmbH, the holder of various patents related to the pen injector device.

Key Points: 
  • Under the agreement, Lannett and HEC will, in exchange for its financial contribution, receive a sub-license to a licensing arrangement between Ypsomed and Sanofi-Aventis Deutschland GmbH, the holder of various patents related to the pen injector device.
  • "In short, we have significantly improved our ability to freely market our biosimilar insulin products, once approved."
  • Lannett previously said that subject dosing has been completed in the pivotal clinical trial of Lannett/HEC's biosimilar insulin glargine and no serious adverse events were reported.
  • Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

The Senior Citizens League Says, "You Better Check Your Medicare Drug Plan"

Retrieved on: 
Monday, October 31, 2022
Insurance, Social Security, Policy, Insulin glargine/lixisenatide, Social, Diabetes, Thought, Insulin, Friends, Association, Formulary, Medicare Advantage, Johnson, Medicare Part D, Retired Enlisted Association, Prescription, SHIP, Insulin lispro, Elijah Cummings Lower Drug Costs Now Act, Ageing, Blood pressure, Folate, CVS, Walgreens, Wind, Health insurance, Pharmaceutical industry, Citizenship, Insulin glargine, Walmart, Medicare

WASHINGTON, Oct. 26, 2022 /PRNewswire-PRWeb/ -- The recently enacted Inflation Reduction Act requires Medicare Part D plans to cap insulin costs at $35 per month per covered prescription starting in 2023, but to get the savings, diabetic Medicare beneficiaries first need to confirm that their insulin will be covered by their plan next year, warns the Senior Citizens League (TSCL). "If your insulin isn't covered by your plan, the $35 cap will not apply and you could wind up with thousands of dollars in pharmacy bills," says Mary Johnson, a Medicare, and Social Security policy analyst for The Senior Citizen League.

Key Points: 
  • For the past 17 years, Johnson has been helping friends and family check and compare their Medicare coverage options during the annual Medicare Open Enrollment Period.
  • Johnson, who has experience doing drug plan searches, immediately hit a dead end on her first search attempt using the Medicare Drug Plan Finder .
  • "The drug input in the Medicare Drug Plan Finder automatically defaults to the generic name of the drug unless the user overrides it and clicks on 'brand.'
  • With 1.2 million supporters, The Senior Citizens League is one of the nation's largest nonpartisan seniors' groups.

Mini Bioreactors and Micro Bioreactors Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022
Health, Biotechnology, Carbon dioxide, Adoption, Rituximab, Oxygen, Precision medicine, Industry, Growth, PH, Geography, Cell culture, Patent, CPC, Benchmarking, CO2, Type, Solution, Bevacizumab, Overalls, Temperature, Fine chemical, Pharmaceutical industry, Marketing, Infliximab, Insulin glargine

The "Mini Bioreactors and Micro Bioreactors Market, Distribution by Type of Cell Culture, Mode of Operation, End User and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mini Bioreactors and Micro Bioreactors Market, Distribution by Type of Cell Culture, Mode of Operation, End User and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • The 'Mini Bioreactors and Micro Bioreactors Market, 2022-2035' report features an extensive study of the current landscape and the likely future potential of minibioreactors and microbioreactors, over the next decade.
  • One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of minibioreactors and microbioreactors market.
  • Presently, more than 55 minibioreactors, developed by around 30 companies, are available for high-throughput media cultivation, process development and optimization.

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

Retrieved on: 
Wednesday, August 3, 2022
Oncology, Professional Services, Health, Insurance, Managed Care, Pharmaceutical, Biotechnology, Pharmacy, Blue Cross, Drug, Prednisone, Health, Blue Shield, Face, PBM, Tablet, Partnership, Patient, Insulin lispro, Insurance, Blue Cross Blue Shield Association, Intermountain Healthcare, Prostate cancer, Sale, Welfare, Insulin aspart, Health Care Service Corporation, CEO, Medication, BCBS, Civica, FDA, Medicare, Prescription, Insulin, Medicare Part D, Dietary supplement, Health insurance, Pharmaceutical industry, Insulin glargine

Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.

Key Points: 
  • Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.
  • Abiraterone was chosen by CivicaScriptmembers as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.
  • This is a proud day for CivicaScript as we advance our mission to make generic medicines affordable and available to everyone, said CivicaScript President Gina Guinasso.
  • CivicaScript then works with like-minded payors, PBMs and pharmacies across the country who pass along the cost savings to their customers.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Retrieved on: 
Friday, June 24, 2022
COVID-19, Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Process, Research, Immortalised cell line, STAR, COVID-19, Delta, Company, Longevity, Volunteering, Serum, Seroconversion, ANVISA, Vaccine, EUA, Stelis, Efficiency, WHO, RNA transfection, Fahrenheit, BSE, Population, Immunization, UK, Omicron, GMP, PD, National Stock Exchange of India, Merck, USFDA, Martek Biosciences Corporation, Insulin glargine, Insulin, Global, Diabetes, CEO, DPH, Peptide, Insulin lispro, Immunoglobulin G, Insulin aspart, Partnership, Technology, Temperature, Merck & Co., Leadership, Stride, SmartCell Technology, National Stock Exchange, Porantha Veeda Puguntha Veeda, CDMO, COVID-19 vaccine, Maintenance, Developing country, Safety, Immunity, Pharmaceutical industry, Fine chemical, Phase

The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).

Key Points: 
  • The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).
  • Akston and Strides group have already signed a licensing, manufacturing, and commercialization agreement to launch this vaccine worldwide as AmbiVax-CTM.
  • The vaccine is a reliable, accessible alternative in these regions, allowing immunization and longevity of immunity with the boosters against the Covid variants of concern.
  • Biolexis Private Limited (Biolexis) is an emerging biotech and vaccine company capable of developing and commercializing products for the Global markets.